The NCI is seeking R01 applications to conduct translational, clinical, therapeutic, and preventive studies/trials of neoplastic diseases in humans and encourages clinical researchers to collaborate with basic scientists to translate insights in cancer biology and the development of new anti-cancer agents into innovative cancer intervention studies/trials. The overall aims of this renewed PA are two-fold: (1) to stimulate development of innovative therapeutic/preventive clinical trials with or without laboratory correlative studies (2) to support innovative correlative laboratory studies linked to therapeutic/preventive clinical trials. Investigators may address either aim in their applications.

• Release Date: December 24, 2003
• Application Receipt Date(s): February 1, June 1, and October 1
• No set-aside
• Contact: Keyvan Farahani, Ph.D. (farahank@mail.nih.gov) at 301-451-2651

See full description in NIH Guide: PA-04-046